OXC-101
Oxcia also receives ODD approval from EMA
Earlier this spring, Oxcia announced that the drug candidate OXC-101 had received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for...
Bioteknik
Intervju
Psoriasis – new opportunity for Oxcia
Oxcia has so far focused on treating cancer...
Intervju
Thomas Helleday and Oxcia in the fight against cancer and inflammation
Thomas Helleday, founder and largest owner of biotechnology company Oxcia,...
Intervju
Oxcia's CEO on the focus on AML and pulmonary fibrosis
Oxcia is now focusing wholeheartedly on developing its...
Intervju